

Rec'd PCT/PTO 20 JUL 2004

10/501808

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
31 July 2003 (31.07.2003)

PCT

(10) International Publication Number  
WO 03/061624 A1

(51) International Patent Classification<sup>7</sup>: A61K 9/00

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/GB03/00301

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 23 January 2003 (23.01.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0201607.9 24 January 2002 (24.01.2002) GB

(71) Applicants and  
(72) Inventors: HEIGHTMAN, Nicholas, John [GB/GB]; 51 Broom Close, Teddington, Middlesex TW11 9RL (GB). GAMLEN, Michael, John, Desmond [GB/GB]; 9 Aldersmead Road, Beckenham, Kent BR3 1NA (GB).

(74) Agents: MERCER, Christopher, Paul et al.; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1 2RA (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/061624 A1

(54) Title: FORMULATION FOR THE ADMINISTRATION OF MEDICINAL SUBSTANCES

(57) Abstract: A formulation for administration of a medicinal substance, comprises a sandwich biscuit having two or more biscuit layers that support filler layer(s), in which the filler layer comprises a dosage unit form, or a multiple or sub-multiple thereof, of a medicament that is unpalatable in having, for example, a gritty texture or a chalky texture or other unpleasant mouth feel. The biscuit layer of the sandwich biscuit may be a plain, non-medicated, biscuit layer or may itself contain a medicament. In the latter instance, it is possible to select a different medicament for the filler layer from that in the biscuit layer, whereby the two medicaments have a co-operating or synergistic effect. The formulations also allow large dosages of drugs to be administered effectively in a palatable form and are suitable for the long-term administration of drugs.

## FORMULATION FOR THE ADMINISTRATION OF MEDICINAL SUBSTANCES

FIELD OF INVENTION

This invention relates to a new formulation for the administration of medicinal substances within traditional baked food products, in particular within sandwich biscuits.

BACKGROUND OF THE INVENTION

Many medicines are potent materials requiring small amounts for their effectiveness, but there are other medicines that must be administered in large doses.

10 Conventional formulations such as tablets and capsules can accommodate up to 1000mg of active ingredient but the products are very large and many patients find them difficult to swallow. In many cases the physical properties of the medicinal substance preclude dosages in excess of 250-500mg as they require dilution in inert materials to render them suitable for processing. Dosages of the order of several or many grammes per day require

15 the patient to take many tablets. Some medicines such as guar gum and cholestyramine resin are presented in sachets for dispersion in water. The products are not very palatable and are inelegant, again resulting in problems with patient acceptability and compliance.

It is known that medicines can be made more palatable or their presence disguised by incorporating the medicines within pre-cooked biscuits that have been reduced to crumb form. However, this requires intervention on behalf of the person making up the mixture and relies on their skill in ensuring that both a full dose of medicine is incorporated within the mixture and that the patient consumes all of the mixture. It is also known that certain therapeutic substances can be incorporated within biscuits during the initial cooking step, but this is not always satisfactory, particularly if the incorporated substance is adversely affected by the cooking process. There thus remains a need to provide alternative formulations for unpalatable medicinal, i.e. pharmaceutically active, substances.

It is the purpose of the present invention to allow the inclusion of active medicinal substances in readily acceptable formulations in such a way that compliance with drug treatment dosage regimes is enhanced. The present invention also addresses the problem

30 of allowing large dosages of drugs to be administered effectively, especially as it has often not previously been convenient to administer such dosages by known administration routes. Many treatment regimes achieve sub-optimal therapeutic results because patients for whom the treatment is prescribed find that it is unpleasant to take the drug in the

amount required and accordingly the patient may either omit taking doses or take them in inadequate quantities. The present invention permits the administration of large amounts of unpalatable material - for example with a gritty texture or a chalky texture or other unpleasant mouth feel, in a product which both palatable and familiar to the patient. This 5 helps to ensure acceptability to the patient, and thereby improve patient compliance.

We have found that the formulation according to the present invention can be adapted to carry relatively high quantities of medicinal drug substances and combination of medicinal substances in such a way that chewing in the mouth facilitates swallowing, without adversely affecting the taste or mouthfeel of the biscuit. This makes the 10 administration of drugs much more acceptable to many patients who find it difficult to swallow conventional pills and capsules. A further advantage is that formulations of the present invention have a texture that masks unpleasant mouth feel, such as gritty texture or chalkiness of some medicinal substances. The new formulations are also particularly suitable for the long-term administration of medicinal substances.

15

#### SUMMARY OF THE INVENTION

According to the present invention there further provided a formulation for the administration of a medical substance comprising a sandwich biscuit having two or more biscuit layers that support filler layer(s), in which the filler layer, and optionally the biscuit 20 layers, comprise(s) a dosage unit form, or a multiple or sub-multiple thereof, of an unpalatable medicament. A further aspect of the invention is that the filler layer can contain a large amount of medicinal substance without having a deleterious effect on the mouth feel or palatability of the product.

The "sandwich biscuit" of the present invention may comprise a cream or other 25 filling layer supported between any convenient number of dry layers, normally two layers, of biscuit. The biscuit layer of the sandwich biscuit may be a plain, non-medicated, biscuit layer or may itself contain a medicament. In the latter instance, it is possible to select a different medicament for the filler layer from that in the biscuit layer, whereby the two medicaments have a co-operating or synergistic effect. As already indicated, a medicine is 30 unpalatable if it cannot be readily orally administered in its simple state, for example because of unpleasant mouth feel.

As indicated previously, the invention is of special value where relatively large amounts of active medicinal ingredient need be taken for the treatment to be effective, for

example an individual dose in excess of 250 mg, particularly in excess of 500mg. Large amounts of medicament includes quantities between 1g and 3g per portion, although even higher quantities may be used in some circumstances. This feature of the invention can be particularly useful in both human and veterinary medicine.

5 The biscuits of the present invention would normally be subjected to a single cooking process and are otherwise known as cookies. Originally biscuits were subjected to two baking steps with the biscuit being dried in the second step. A rusk or similar product such as ships biscuits would be the result. Although such biscuits are long lasting, the second cooking step would normally be avoided in the present invention to prevent thermal  
10 damage to the medicinal compound and to make the product more palatable. Nevertheless, special technical steps must be taken to preserve the freshness of biscuits of the present invention as a considerably longer shelf life is contemplated for pharmaceuticals. For example, pharmaceuticals are often stored for up to 18 months, whereas baked products are normally consumed within a few weeks at the most. Appropriate steps for the long-term  
15 preservation of medical biscuits according to the invention might be the incorporation of suitable preservative substances or the use of specialised packaging materials to prevent the ingress of moisture and oxygen. Of course there may be occasions when it would be appropriate to store the medicated filling separately and arrange for the formation of the sandwich biscuit close to the anticipated date of consumption.

20 The sandwich biscuit embodiment of the present invention in which the medicament is only in the filling layer would be adopted if the medicament is heat sensitive and cannot be incorporated in the biscuit composition during the cooking stage without degradation.

25 The biscuits of the present invention would normally be prepared within food factories where the existing strict hygiene and quantity monitoring would be easily adapted to the strict requirements of the pharmaceutical industry. The various techniques for biscuit making on the domestic scale are generally adaptable to factory scale production. The main criterion for the suitability of a particular technique is the need to ensure that the weight and thus dosage of the individual portions of the resulting cooked biscuits can be  
30 tightly controlled. Examples of appropriate techniques are dropped cookies where soft dough is spooned directly on to the baking sheet in predetermined portions, shaped cookies where a predetermined portion is cut from soft dough, piped cookies where a relatively

fluid mixture is piped onto a baking tray and bar cookies, such as flapjacks, in which a large block is produced and then cut after cooking into suitably sized portions.

Biscuit formulations can be prepared from a number of conventional ingredients and it is possible to select particular ingredients on the basis of their appropriateness to the 5 disease to be treated. For example, if cholesterol reduction were the object of the therapy it would be possible to base a biscuit on a formulation on oats, which is a material that is believed to have additional therapeutic effect in lowering cholesterol. Such a biscuit layer would then be used in conjunction with a cholesterol lowering medicament in the filling layer.

10 In one embodiment the present invention accordingly provides a sandwich biscuit in which the medicinal substance in the biscuit and the medicament in the filler layer have a co-operating or synergistic effect on administration.

For the treatment of renal failure, sandwich biscuits contain an ion exchange resin substance VML252 with, or without a combination of calcium carbonate in the filler layer, 15 or in both filler and biscuit layers, would be appropriate. This formulation would be used to treat elevated blood phosphate levels encountered by patients undergoing renal dialysis. This is one of the instances mentioned previously in which very high dosages of medicines are required and are difficult to present to the patient in an acceptable form in other ways. The presence of the medicament in both layers would be particularly appropriate in this 20 instance. A typical dosage for the administration of such ion exchange resins would be approximately 8-12 g/day. Other treatments for hyperphosphataemia such as lanthanum carbonate and sevelamer hydrochloride (Renagel )

As already indicated, lowering cholesterol levels is also a possible treatment and sandwich biscuits for this purpose may contain the ion exchange resin, cholestyramine 25 with, or without, other active substances including clofibrate, gemfibrozil and other orally active cholesterol-lowering materials. Again high dosages may be necessary and a dosage of approximately 12g/day of cholestyramine is typical.

Worm control in pets and farm animals may be based on sandwich biscuits formulated comprising anthelmintic agents for example, albendazole, febendazole 30 (Panacura<sup>®</sup>), Ivermectin, thiabendazole and other bendazole substances. Appropriate version of such anthelmintic formulations also may be used in human medicine.

For the treatment of diabetes type 2, sandwich biscuit formulation containing metformin or combinations of other oral agents with metformin would be appropriate, as

would biscuit formulations with gamma guanidinobutyramide and its pharmaceutically acceptable salts together with combinations of other agents used to treat diabetes type 2. Appropriate dosages of these active ingredients would be 200 to 2000mg.

Where a patient suffers from excessive serum potassium, sandwich biscuit 5 formulations containing the ion exchange resin and combinations of other oral agents used for treating elevated serum potassium would be appropriate.

The following examples are provided to further illustrate the present invention

Example 1

A semi-sweet biscuit enriched with calcium carbonate was prepared from the 10 following ingredients:

	Plain flour	250g
	Sugar	50g
	Margarine	40g
15	Salt	3g
	Calcium carbonate	53g
	Water to mix	110g

The flour, salt and calcium carbonate were mixed together and the margarine 20 rubbed in until the mixture resembled fine breadcrumbs. Water was added to form a firm dough, which was rested for 15 minutes. The dough was rolled to a thickness of about 2 mm and cut into circles weighing 7.5g, so that each baked biscuit contained approximately 1g of calcium carbonate.

The biscuits were baked on a greased baking sheet in a pre-heated oven at 190°C 25 for 5 minutes until a pale golden brown colour. The biscuits were then removed from the oven and allowed to cool.

The cream-filling was prepared using a cream made from the following ingredients:

30	Icing sugar	237g
	Fat	240g
	Lecithin	0.6g
	Salt	0.3g

Vanilla liquid essence 1.8g  
Calcium carbonate 120g

The ingredients were mixed together to form a cream filling of which 5g, containing 1g  
5 calcium carbonate, was deposited between two semi-sweet biscuits, prepared as described  
above. This provided a total dose of 3g calcium carbonate per biscuit. The biscuits were  
stored in an airtight container.

Example 2

A digestive biscuit enriched with calcium carbonate was prepared from the  
10 following ingredients:

	Plain flour	160g
	Wheatmeal flour	45g
	Margarine	65g
15	Caster sugar	15g
	Demerara sugar	35g
	Golden syrup	15g
	Calcium carbonate	30g
	Salt	2g
20	Water	50g

The margarine, sugars and syrup were creamed together for 3 minutes and the dry  
ingredients folded into the resultant mixture. Water was added to form a firm dough,  
which was rested for 15 minutes. The dough was rolled to a thickness of about 3mm and  
25 cut into circles weighing 14g, so that each baked biscuit contained approximately 1g of  
calcium carbonate.

The biscuits were baked on a greased baking sheet in a pre-heated oven at 185°C  
for 6 minutes until a golden brown colour. The biscuits were then removed from the oven  
and allowed to cool.

30 A cream filling prepared as described in Example 1 was deposited between two  
biscuits. This provided a total dose of 3g calcium carbonate per biscuit. The biscuits were  
stored in an airtight container.

Example 3

A semi-sweet biscuit containing an ion exchange resin VML 252 was prepared from the following ingredients:

5	Flour	500g
	Sugar	104g
	Fat	80g
	Glucose	6.5g
	Salt	6g
10	Sodium bicarbonate	2.5g
	Ammonium bicarbonate	5g
	VML 252	107g
	Water to mix	220g

15 The dough was mixed until a temperature of 40°C was reached. The VML 252 was added to the dough mix and mixed until evenly distributed.

The dough was rested for 15 minutes before being formed into sheets of a thickness of 3mm and cut into circles weighing 7.5g, so that each baked biscuit contained approximately 1g of VML 252.

20 The biscuits were baked on a greased baking sheet in a pre-heated oven at 190°C for 5.5 minutes until a pale golden brown colour. After being removed from the oven and allowed to cool, the biscuits were stored in an airtight container.

The cream-filling was prepared using a cream made from the following ingredients:

25	Icing sugar	237g
	Fat	240g
	Lecithin	0.6g
	Salt	0.3g
	Vanilla liquid essence	1.8g
30	VML 252	120g

The ingredients were mixed together to form a cream filling. 5g of the filling containing 1g VML 252 was deposited between two semi-sweet biscuits, prepared as

described in Example 5. This provided a total dose of 3g VML 252 per biscuit. The biscuits were stored in an airtight container.

Example 4

A low salt snack cracker was prepared from the following ingredients:

5

	Fat (reduced fat spread rich in monounsaturates)	160g
	Salt	13g
	Skimmed milk powder	16g
10	Flour	800g
	Ammonium bicarbonate	20g
	Sodium metabisulphite	10g
	Water	450g

15 The ingredients were added in the above order and blended together for 1 minute. The dough was then mixed at 120 rpm for 3.5 minutes. The dough was rested for 15 minutes before being formed into sheets and laminated to a final thickness of 2mm.

The dough was cut into circles weighing 8g. The crackers were baked at 230°C for 4.5 minutes. After being removed from the oven, the crackers were allowed to cool.

20 A cream cheese filling containing gamma guanidinobutyramide (an antidiabetic agent) was prepared using a cream made from the following ingredients:

	Fat (reduced fat spread rich in monounsaturates)	240g
25	Lecithin	0.6g
	Cheese flavouring	2.0g
	Gamma guanidinobutyramide	2.0g

30 The cream filling was added between two biscuit layers in an amount that provided 200 to 2000mg of gamma guanidinobutyramide per sandwich biscuit. The biscuits were then stored in an airtight container.

Example 5

A low salt snack cracker was prepared as described in Example 4.

A cream cheese filling containing metformin (an antidiabetic agent) was prepared using a cream made from the following ingredients:

5

Fat (reduced fat spread rich in monounsaturates)	240g
Lecithin	0.6g
Cheese flavouring	2.0g
Metformin	2.0g

10

The cream filling was added between two biscuit layers in an amount that provided 200 to 2000mg of metformin per sandwich biscuit. The biscuits were then stored in an airtight container.

15 Example 6

Semi sweet biscuits were prepared as described in Example 1, but with the omission of the calcium carbonate component.

A biscuit cream filling was prepared by creaming together the following ingredients:

20

Icing sugar	100g
Vegetable shortening	60g
Lanthanum carbonate	40g
Lemon/vanilla flavouring	trace

25

A 5g portion of the cream filling was sandwiched between two semi-sweet biscuits. Each cream biscuit provided 1g lanthanum carbonate.

Example 7

A serving of medicated biscuit was prepared from two 'morning coffee' biscuits sandwiched together with 10g cream containing 3g Renagel® (sevelamer hydrochloride).

The Renagel® cream filling was prepared by blending together the following components to form a soft cream:

Icing sugar	40g
Vegetable shortening	30g
Renagel	30g
Lemon flavouring	trace

5

The filling and biscuits, respectively had the following nutritional properties:

<u>Filling nutritional composition</u>	per 100g	per 10g serving
Energy	1782 kJ; 428 kcal	178 kJ; 43 kcal
Protein	0 g	0 g
Carbohydrate (as sugars)	42.0 g	4.2 g
Fat	30.0 g	3.0 g
Saturates	6.3 g	0.6 g

10

Nutritional composition of each cream biscuit

Energy	368 kJ; 89 kcal
Protein	0.8 g
Carbohydrate	11.6 g
Sugars	6.0 g
Fat	4.4 g
Saturates	1.2 g
Sodium	less than 0.1g

It will, of course, be understood that the present invention has been described above purely by way of example and that modifications of detail can be made within the scope of this invention.

CLAIMS

1. A formulation for the administration of a medicinal substance comprising a sandwich biscuit comprising one or more biscuit layers that support filler layers wherein  
5 the filler layer comprises a dosage unit form or multiple or sub-multiple layer thereof of an unpalatable medicament.
- 10 2. A formulation according to claim 1, in which the medicament has a gritty texture or a chalky texture or other unpleasant mouth feel.
3. A formulation according to claim 1 or 2, in which the medicament is present in an amount of greater than 500 mg per biscuit.
- 15 4. A formulation according to claim 3, in which the medicament is present in an amount of between 1g and 3g per biscuit
5. A formulation according to any of the foregoing claims, in which the medicinal substance is selected from the ion exchange resin substance VML252, optionally in combination of calcium carbonate, the ion exchange resin cholestyramine, optionally in  
20 combination chlofibrate, gemfibrozil and other orally active cholesterol-lowering materials, anthelmintic agents, metformin or gamma guanidinobutyramide and its pharmaceutically acceptable salts, optionally in combination of other oral agents used to treat diabetes type 2, carboxyl-methyl-cellulose and carboxyl-ethyl-cellulose, optionally in combination with other agents for the oral treatment of obesity, and ion exchange resin  
25 suitable for treating elevated serum potassium, optionally in combination of with other oral agents used for treating elevated serum potassium.
- 30 6. A formulation according to claim 5, in which the anthelmintic agent is albendazole, febendazole, Ivermectin, thiabendazole and another bendazole substances
7. A formulation according to any of the foregoing claims comprising a biscuit layers comprise a medical substance, in which the medicinal substance in the biscuit and the medicament in the filler layer have a co-operating or synergistic effect on administration.

8. A formulation according to any of claims 1 to 6, in which the biscuit layer is an oatmeal biscuit and the medicament is a cholesterol lowering pharmaceutical.
9. A formulation according to claim 1, substantially as hereinbefore described in any  
5 one of the Examples.

## INTERNATIONAL SEARCH REPORT

Inte 59 Application No  
PCT/GB 03/00301A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K9/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EMBASE, EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 306 469 A (PROCTER & GAMBLE) 8 March 1989 (1989-03-08) page 1, line 8 - line 57 page 4, line 40 page 4, line 47 - line 50 examples 1-3 ---	1-9
X	GB 993 308 A (Pfizer LTD) 26 May 1965 (1965-05-26) page 1, left-hand column, line 39 -right-hand column, line 60 page 1, right-hand column, line 82 - line 86 examples 1,2 claims 1,2 --- -/-	1-9

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search  20 June 2003	Date of mailing of the international search report  03/07/2003
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel: (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer  VON EGGEKRAUT, S

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 03/00301

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 939 127 A (ABBOUD AMNA MUNJI) 17 August 1999 (1999-08-17) column 2, line 37 - line 47 column 5, line 45 - line 53 example 1 ----	1-9
A	EP 0 347 014 A (BASF K & F CORP) 20 December 1989 (1989-12-20) page 2, line 15 - line 19 page 2, line 29 - line 55 page 4, line 48 - line 55 ----	1-9
A	EP 0 950 357 A (NOVO INC DE) 20 October 1999 (1999-10-20) paragraph '0032! - paragraph '0035! ----	1-9
A	GEMMELL M A ET AL: "Treatment of <i>Taenia hydatigena</i> infections in dogs with bunamidine hydroxynaphthoate incorporated in food" NEW ZEALAND VETERINARY JOURNAL 1975, vol. 23, no. 7, 1975, pages 142-144, XP001159610 page 142, right-hand column, paragraph 3 page 143, right-hand column, last paragraph -page 144, left-hand column, paragraph 1 ----	1-9

## INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte ~~nter~~ Application No

PCT/GB 03/00301

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
EP 0306469	A 08-03-1989		AT 72944 T AU 2181388 A DE 3868793 D1 EP 0306469 A1 ES 2033464 T3 GR 3003973 T3 JP 1132353 A US 5143728 A	15-03-1992 09-03-1989 09-04-1992 08-03-1989 16-03-1993 16-03-1993 24-05-1989 01-09-1992
GB 993308	A 26-05-1965	MY	5767 A	31-12-1967
US 5939127	A 17-08-1999	US US CA CA	5851576 A 5658609 A 2201462 A1 2150515 A1	22-12-1998 19-08-1997 30-10-1997 30-12-1995
EP 0347014	A 20-12-1989	US AU AU CA EP JP JP US	4931280 A 618104 B2 3715789 A 1329775 C 0347014 A1 2695247 B2 3091434 A 5015477 A	05-06-1990 12-12-1991 03-01-1991 24-05-1994 20-12-1989 24-12-1997 17-04-1991 14-05-1991
EP 0950357	A 20-10-1999	US EP CA US	5795586 A 0950357 A1 2193770 A1 6294189 B1	18-08-1998 20-10-1999 08-02-1998 25-09-2001